The FDA had on July 6 issued a show cause notice to GPI asking them why legal action should not be initiated against them for selling e-cigarettes and violating provisions of the Drugs and Cosmetics Act and the Cigarettes and Other Tobacco Products Act.

In a reprieve for e-cigarette manufacturers and distributors, the Bombay high court (HC) on Friday allowed them to resume sale of the product as it is not a drug. Observing that the action taken against them by the Food and Drugs Administration (FDA) was not sustainable, the HC directed it to release the seized stock of e-cigarettes.

Read more about this article here: https://www.hindustantimes.com/cities/e-cigarettes-not-drug-traders-can-resume-sale-says-bombay-high-court/story-5u2yAukIKlzTofvoU10F2J.html

During last week’s congressional hearings surrounding a perceived rise in teen vaping rates, Juul CEO Kevin Burns came under consistent attack by federal lawmakers regarding the company’s alleged role. As the hearings conducted by the House Subcommittee on Economic and Consumer Policy got underway, it quickly became painfully obvious that the event was not designed to be a true fact-finding mission.  Rather, many committee members would simply use his or her 5-minutes of questioning to rant, rave, and spread grossly misinformed and utterly biased opinions regardless of scientific evidence.

https://www.vapes.com/blogs/news/renowned-epidemiologist-debunks-fda-claims-of-teen-vaping-epidemic

At several points during the congressional back-and-forth, the topic of vaping science was highlighted ever so slightly.  A common fallback position of anti-vaping activists is that more research is needed before academia, and consequently lawmakers supposedly, can claim definitively whether vapor products are safe for human consumption.

Read more about this article here: https://www.vapes.com/blogs/news/renowned-epidemiologist-debunks-fda-claims-of-teen-vaping-epidemic